Site-Specific Protein PEGylation via Controlled Radical Polymerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for modifying therapeutic proteins, such as PEGylation, face challenges including suboptimal yields, random attachment of polymers, and variable activity due to non-specific linking technologies, which affect the efficacy and stability of protein-based treatments.
Innovation Solution
The development of novel polymers using controlled architecture methods like atom transfer radical polymerization (ATRP) and radical addition-fragmentation chain transfer polymerization (RAFT) for selective attachment to biological molecules, particularly through thiol groups, ensuring consistent and targeted conjugation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional PEGylation methods are used to prolong circulation time, then pharmacokinetic properties are improved, but manufacturing precision deteriorates due to random attachment at multiple sites
Solution Approach 1:
The invention introduces site-specific conjugation by targeting particular amino acid residues (such as lysine or cysteine) on the protein surface. This ensures that PEG attachment occurs at defined locations rather than randomly throughout the protein, maintaining manufacturing precision while achieving the desired pharmacokinetic improvements through controlled local modification.
Solution Approach 2:
The methodology employs preliminary site selection and preparation steps, including the use of affinity tags or engineered cysteine residues at specific positions. This preliminary action ensures that subsequent PEGylation occurs only at predetermined sites, resolving the contradiction between random attachment and controlled conjugation.
2Ease of manufacture
If random PEGylation is performed to simplify the process, then ease of manufacture is improved, but product homogeneity deteriorates due to variable activities
Solution Approach 1:
The invention changes the chemical parameters of the conjugation reaction by using site-specific reactive groups (such as maleimide-thiol chemistry or engineered lysine residues). This parameter change allows for controlled conjugation at specific sites while maintaining process simplicity, thus achieving both ease of manufacture and product homogeneity.
Solution Approach 2:
The methodology introduces intermediary structures such as affinity tags, self-immolative linkers, or engineered peptide sequences that mediate the conjugation process. These intermediaries guide the PEG attachment to specific sites while simplifying the overall manufacturing process through modular design.
3Quantity of substance
If multiple PEG chains are attached to increase bioavailability, then pharmacokinetic properties are improved, but loss of substance increases due to 20-40% protein and PEG-agent losses
Solution Approach 1:
The invention employs self-service mechanisms where the protein itself provides the attachment sites through engineered residues or native functional groups. This eliminates the need for excess PEG reagents and reduces losses by ensuring stoichiometric conjugation, thereby improving bioavailability while minimizing substance loss.
Solution Approach 2:
The methodology incorporates feedback mechanisms through controlled reaction conditions and real-time monitoring of conjugation progress. This allows for optimization of reaction stoichiometry and minimization of unreacted materials, reducing losses while achieving the desired level of PEGylation for improved bioavailability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for high-control polymerization processes that enhance the stability, bioactivity, and pharmacokinetic properties of therapeutic proteins, reducing immunogenicity and toxicity, and providing a more stable and effective therapeutic profile.
Implementation Method 1
polymers of controlled architecture made using such methods known in the art as atom transfer radical polymerisation (ATRP)
Implementation Method 2
radical addition-fragmentation chain transfer polymerisation (RAFT)
Implementation Method 3
PEG polymer chains can sustain bioavailability by protecting the drug molecules from immune responses and other clearance mechanisms
Implementation Method 4
conjugate thiol groups of two cysteine residues in a protein to give novel thioether conjugates
Data Source
Figure 1
Figure 2
Figure 3a~3b
AI summary
The present invention relates to a new polymerisation process in which ethylenically unsaturated monomers are polymerised by a living radical polymerisation process in the presence of an initiator and a catalyst. Polymers produced by this new process are also thought to be novel and may be used to derivatise biological molecules to improve their efficacy as therapeutic treatments. A preferred polymer is of formula (A) The polymers are particularly suitable for derivatising proteins, such as interferon.